

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

X



Memorial Sloan Kettering
Cancer Center

[About Us](#)
[Sloan Kettering Institute](#)

The Michael Kharas Lab

[Research](#)


Ly Vu, PhD

[Education & Training](#)

Assistant Professor, Simon Fraser University, Vancouver, BC, Canada

[News & Events](#)

[Open Positions](#)



[Email](#)

vul@mskcc.org

Dissertation

The Role of Protein Arginine Methyltransferase – 4 (PRMT4) in normal and malignant hematopoiesis (2013)

Mentor

Stephen D. Nimer

End Year

2013

Education

Dai hoc Quoc Gia Hanoi

Publications

[Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. \(2016\) MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. *Nat Commun.*, 7, 10739. PMCID: PMC4764878.](#)

[Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD. \(2015\) The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells. *Stem Cell Reports*, 4, 658-69. PMCID: PMC4400644.](#)

[Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, Levine R, Leslie C, Lengner CJ, Kharas MG. \(2015\) Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. *J Clin Invest.* 125, 1286-98. PMCID: PMC4362230](#)

[Vu L, Luciani L, Nimer S. \(2013\) Histone-modifying enzymes: their role in the pathogenesis of acute leukemia and their therapeutic potential. *Int J Hematol*, 97, 198-209.](#)

[Vu L, Perna F, Wang L, Voza F, Figueroa M, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer S. \(2013\) PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. *Cell Rep*, 5, 1625-1638.](#)

[Moulick K, Ahn J, Zong H, Rodina A, Cerchietti L, Gomes Dagama E, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu L, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross S, Pillarsetty N, Ku T, Lewis J, Larson S, Levine R, Erdjument-Bromage H, Guzman M, Nimer S, Melnick A, Neckers L, Chiosis G. \(2011\) Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. *Nat Chem Biol*, 7, 818-826.](#)

[Wang L, Gural A, Sun X, Zhao X, Perna X, Huang G, Hatlen M, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole P, Zhang J, Melnick A, Roeder R, Nimer S. \(2011\). The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. *Science*, 333, 765-769.](#)

[Wang L, Huang G, Zhao X, Hatlen M, Vu L, Liu F, Nimer S. \(2009\) Post-translational modifications of Runx1 regulate its activity in the cell. *Blood Cells Mol Dis*, 43, 30-34.](#)

[View a full listing of Ly Vu's journal articles.](#)

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center